A program focused on the study of the interaction between susceptibility genes and environmental factors (including lifestyle) in the causation of cancer. The program has conducted an ongoing series of studies examining the interaction between genetic predisposition and environmental and lifestyle factors for non-Hodgkin lymphoma, melanoma, and multiple myeloma, as well as breast, ovarian, prostate, bladder and skin cancers.
Gene-Environment Interactions in Cancer Research (GENIC)
Dr. Nhu Le, PhD
Dr. Terry Boyle, PhD
Dr. Angela Brooks-Wilson, PhD
Dr. Kristin Campbell, PhD
Dr. Derrick Lee, PhD
Dr. Anne-Marie Nicol, PhD
Agnes Lai, MSc
Skin Health and Environment (S.H.E. Study)
It is known that ultraviolet light exposure causes melanoma. However, it is not clear whether there are other environmental factors acting along with ultraviolet radiation. This study investigates the role of organochlorine compounds, found in the environment, in melanoma development.
Prognosis and risk factors of skin cancer
This multi- institute project (InterMEL consortium project) identifies molecular and clinical factors which relate to the prognosis of melanoma, with the ultimate objective of improving the treatment of advanced melanoma.
Discovering genetic susceptibility factors for breast cancer in an innovative international consortium
This project aims to discover new markers of breast cancer through an international effort focused on low-penetrance alleles that, in combination, have a high probability of explaining a large proportion of breast cancer risk.
Epigenomic markers of circulating cell-free DNA and treatment response in multiple myeloma
Multiple Myeloma (MM) is generally incurable and patients will eventually develop relapsed/refractory disease. Early relapse is associated with poor clinical outcomes and overall survival. There are currently no effective markers that can predict which patients will have early relapse.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.